Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Safety and PK of NUV001 in Healthy Adults
NCT06133478Phase 1Completed
- Sponsor
- Nuvamid
- Start
- Nov 2023
- Primary completion
- Mar 2024
- Modality
- Dietary Supplement
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of NUV001 in sickle cell disease (SCD), sponsored by Nuvamid. Primary endpoints: Incidence of treatment-emergent adverse events, Incidence of treatment-emergent clinically significant changes in vital signs and 2 more. Started Nov 2023; status: completed.
02
Drugs
NUV001
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT06133478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06133478.